BACKGROUND: Despite the favorable results of imatinib front line in chronic-phase chronic myeloid leukemia there is room for improvement. DESIGN AND METHODS: Early intervention during imatinib therapy was undertaken in 210 adults with chronic-phase chronic myeloid leukemia less than three months from diagnosis (Sokal high risk: 16%). Patients received imatinib 400 mg/day. At three months, dose was increased if complete hematologic response was not achieved. At six months, patients in complete cytogenetic response were kept on 400 mg and the remainder randomized to higher imatinib dose or 400 mg plus interferon-alfa. At 18 months, randomized patients were switched to a 2(nd) generation tyrosine kinase inhibitor if not in complete cytogenetic response and imatinib dose increased in non-randomized patients not in major molecular response. RESULTS: Seventy-two percent of patients started imatinib within one month from diagnosis. Median follow-up is 50.5 (range: 1.2-78) months. At three months 4 patients did not have complete hematologic response; at six months 73.8% were in complete cytogenetic response; among the remainder, 9 could not be randomized (toxicity or consent withdrawal), 17 were assigned to high imatinib dose, and 15 to 400 mg + interferon-alpha. The low number of randomized patients precluded comparison between the two arms. Cumulative response at three years was: complete hematologic response 98.6%, complete cytogenetic response 90% and major molecular response 82%. On an intention-to-treat basis, complete cytogenetic response was 78.8% at 18 months. At five years, survival was 97.5%, survival free from accelerated/blastic phase 94.3%, failure free survival 82.5%, and event free survival (including permanent imatinib discontinuation) 71.5%. CONCLUSIONS: These results indicate the benefit of early intervention during imatinib therapy (ClinicalTrials.gov Identifier: NCT00390897).
RCT Entities:
BACKGROUND: Despite the favorable results of imatinib front line in chronic-phase chronic myeloid leukemia there is room for improvement. DESIGN AND METHODS: Early intervention during imatinib therapy was undertaken in 210 adults with chronic-phase chronic myeloid leukemia less than three months from diagnosis (Sokal high risk: 16%). Patients received imatinib 400 mg/day. At three months, dose was increased if complete hematologic response was not achieved. At six months, patients in complete cytogenetic response were kept on 400 mg and the remainder randomized to higher imatinib dose or 400 mg plus interferon-alfa. At 18 months, randomized patients were switched to a 2(nd) generation tyrosine kinase inhibitor if not in complete cytogenetic response and imatinib dose increased in non-randomized patients not in major molecular response. RESULTS: Seventy-two percent of patients started imatinib within one month from diagnosis. Median follow-up is 50.5 (range: 1.2-78) months. At three months 4 patients did not have complete hematologic response; at six months 73.8% were in complete cytogenetic response; among the remainder, 9 could not be randomized (toxicity or consent withdrawal), 17 were assigned to high imatinib dose, and 15 to 400 mg + interferon-alpha. The low number of randomized patients precluded comparison between the two arms. Cumulative response at three years was: complete hematologic response 98.6%, complete cytogenetic response 90% and major molecular response 82%. On an intention-to-treat basis, complete cytogenetic response was 78.8% at 18 months. At five years, survival was 97.5%, survival free from accelerated/blastic phase 94.3%, failure free survival 82.5%, and event free survival (including permanent imatinib discontinuation) 71.5%. CONCLUSIONS: These results indicate the benefit of early intervention during imatinib therapy (ClinicalTrials.gov Identifier: NCT00390897).
Authors: Andreas Hochhaus; Hagop M Kantarjian; Michele Baccarani; Jeffrey H Lipton; Jane F Apperley; Brian J Druker; Thierry Facon; Stuart L Goldberg; Francisco Cervantes; Dietger Niederwieser; Richard T Silver; Richard M Stone; Timothy P Hughes; Martin C Muller; Rana Ezzeddine; Athena M Countouriotis; Neil P Shah Journal: Blood Date: 2006-11-30 Impact factor: 22.113
Authors: Michele Baccarani; Giuseppe Saglio; John Goldman; Andreas Hochhaus; Bengt Simonsson; Frederick Appelbaum; Jane Apperley; Francisco Cervantes; Jorge Cortes; Michael Deininger; Alois Gratwohl; François Guilhot; Mary Horowitz; Timothy Hughes; Hagop Kantarjian; Richard Larson; Dietger Niederwieser; Richard Silver; Rudiger Hehlmann Journal: Blood Date: 2006-05-18 Impact factor: 22.113
Authors: Brian J Druker; François Guilhot; Stephen G O'Brien; Insa Gathmann; Hagop Kantarjian; Norbert Gattermann; Michael W N Deininger; Richard T Silver; John M Goldman; Richard M Stone; Francisco Cervantes; Andreas Hochhaus; Bayard L Powell; Janice L Gabrilove; Philippe Rousselot; Josy Reiffers; Jan J Cornelissen; Timothy Hughes; Hermine Agis; Thomas Fischer; Gregor Verhoef; John Shepherd; Giuseppe Saglio; Alois Gratwohl; Johan L Nielsen; Jerald P Radich; Bengt Simonsson; Kerry Taylor; Michele Baccarani; Charlene So; Laurie Letvak; Richard A Larson Journal: N Engl J Med Date: 2006-12-07 Impact factor: 91.245
Authors: J Hasford; M Pfirrmann; R Hehlmann; N C Allan; M Baccarani; J C Kluin-Nelemans; G Alimena; J L Steegmann; H Ansari Journal: J Natl Cancer Inst Date: 1998-06-03 Impact factor: 13.506
Authors: J E Sokal; E B Cox; M Baccarani; S Tura; G A Gomez; J E Robertson; C Y Tso; T J Braun; B D Clarkson; F Cervantes Journal: Blood Date: 1984-04 Impact factor: 22.113
Authors: Timothy Hughes; Michael Deininger; Andreas Hochhaus; Susan Branford; Jerald Radich; Jaspal Kaeda; Michele Baccarani; Jorge Cortes; Nicholas C P Cross; Brian J Druker; Jean Gabert; David Grimwade; Rüdiger Hehlmann; Suzanne Kamel-Reid; Jeffrey H Lipton; Janina Longtine; Giovanni Martinelli; Giuseppe Saglio; Simona Soverini; Wendy Stock; John M Goldman Journal: Blood Date: 2006-03-07 Impact factor: 22.113
Authors: Tim P Hughes; Jaspal Kaeda; Susan Branford; Zbigniew Rudzki; Andreas Hochhaus; Martee L Hensley; Insa Gathmann; Ann E Bolton; Iris C van Hoomissen; John M Goldman; Jerald P Radich Journal: N Engl J Med Date: 2003-10-09 Impact factor: 91.245
Authors: F Castagnetti; G Gugliotta; M Breccia; F Stagno; A Iurlo; F Albano; E Abruzzese; B Martino; L Levato; T Intermesoli; P Pregno; G Rossi; F Gherlinzoni; P Leoni; F Cavazzini; C Venturi; S Soverini; N Testoni; G Alimena; M Cavo; G Martinelli; F Pane; G Saglio; G Rosti; M Baccarani Journal: Leukemia Date: 2015-06-19 Impact factor: 11.528
Authors: M Pfirrmann; M Baccarani; S Saussele; J Guilhot; F Cervantes; G Ossenkoppele; V S Hoffmann; F Castagnetti; J Hasford; R Hehlmann; B Simonsson Journal: Leukemia Date: 2015-09-29 Impact factor: 11.528
Authors: D Kottwitz; H El Hadi; M El Amrani; S Cabezas; H Dehbi; S Nadifi; A Quessar; D Colomer; Abdeladim Moumen; E L Hassan Sefrioui Journal: Int J Hematol Date: 2015-08-05 Impact factor: 2.490
Authors: Michele Baccarani; Michael W Deininger; Gianantonio Rosti; Andreas Hochhaus; Simona Soverini; Jane F Apperley; Francisco Cervantes; Richard E Clark; Jorge E Cortes; François Guilhot; Henrik Hjorth-Hansen; Timothy P Hughes; Hagop M Kantarjian; Dong-Wook Kim; Richard A Larson; Jeffrey H Lipton; François-Xavier Mahon; Giovanni Martinelli; Jiri Mayer; Martin C Müller; Dietger Niederwieser; Fabrizio Pane; Jerald P Radich; Philippe Rousselot; Giuseppe Saglio; Susanne Saußele; Charles Schiffer; Richard Silver; Bengt Simonsson; Juan-Luis Steegmann; John M Goldman; Rüdiger Hehlmann Journal: Blood Date: 2013-06-26 Impact factor: 22.113